AC Immune SA (ACIU)
2.40
+0.01
(+0.42%)
USD |
NASDAQ |
May 06, 16:00
2.40
0.00 (0.00%)
After-Hours: 20:00
AC Immune Cash from Investing (Quarterly): 25.14M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 25.14M |
September 30, 2023 | 6.088M |
June 30, 2023 | -4.332M |
March 31, 2023 | 46.22M |
December 31, 2022 | 5.446M |
September 30, 2022 | -5.321M |
June 30, 2022 | 25.38M |
March 31, 2022 | -0.5846M |
December 31, 2021 | -23.92M |
September 30, 2021 | -0.2653M |
June 30, 2021 | -33.66M |
March 31, 2021 | -0.8734M |
December 31, 2020 | 3.941M |
September 30, 2020 | 16.51M |
June 30, 2020 | 9.986M |
March 31, 2020 | -0.2191M |
December 31, 2019 | -5.101M |
September 30, 2019 | -11.51M |
Date | Value |
---|---|
June 30, 2019 | -0.0142M |
March 31, 2019 | -50.69M |
December 31, 2018 | -31.01M |
September 30, 2018 | -0.1431M |
June 30, 2018 | -0.3707M |
March 31, 2018 | -1.223M |
December 31, 2017 | 0.0364M |
September 30, 2017 | -0.3189M |
June 30, 2017 | -0.9492M |
March 31, 2017 | -0.6383M |
December 31, 2016 | -0.2843M |
September 30, 2016 | -0.3121M |
June 30, 2016 | -0.1048M |
March 31, 2016 | -0.2114M |
December 31, 2015 | -0.0059M |
September 30, 2015 | -0.1235M |
June 30, 2015 | -0.0391M |
March 31, 2015 | -0.0851M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-33.66M
Minimum
Jun 2021
46.22M
Maximum
Mar 2023
2.784M
Average
-0.2191M
Median
Mar 2020
Cash from Investing (Quarterly) Benchmarks
CRISPR Therapeutics AG | -81.45M |
Addex Therapeutics Ltd | -0.0012M |
NLS Pharmaceutics Ltd | -- |
Molecular Partners AG | 21.20M |
MoonLake Immunotherapeutics | 116.87M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -17.21M |
Cash from Financing (Quarterly) | 45.65M |
Free Cash Flow | -68.17M |
Free Cash Flow Per Share (Quarterly) | -0.2004 |
Free Cash Flow to Equity (Quarterly) | -17.38M |
Free Cash Flow to Firm (Quarterly) | -17.38M |
Free Cash Flow Yield | -33.44% |